Rapamycin fed late in life extends lifespan in genetically heterogeneous mice

David E. Harrison (), Randy Strong, Zelton Dave Sharp, James F. Nelson, Clinton M. Astle, Kevin Flurkey, Nancy L. Nadon, J. Erby Wilkinson, Krystyna Frenkel, Christy S. Carter, Marco Pahor, Martin A. Javors, Elizabeth Fernandez and Richard A. Miller
Additional contact information
David E. Harrison: The Jackson Laboratory, Bar Harbor, Maine 04609, USA
Randy Strong: Geriatric Research, Education and Clinical Center and Research Service, South Texas Veterans Health Care System, and Barshop Institute for Longevity and Aging Studies, The University of Texas Health Science Center at San Antonio, Texas 78229, USA
Zelton Dave Sharp: and Barshop Institute for Longevity and Aging Studies, The University of Texas Health Science Center at San Antonio, Texas 78245, USA
James F. Nelson: Texas 78229, USA
Clinton M. Astle: The Jackson Laboratory, Bar Harbor, Maine 04609, USA
Kevin Flurkey: The Jackson Laboratory, Bar Harbor, Maine 04609, USA
Nancy L. Nadon: National Institute on Aging, Bethesda, Maryland 20892, USA
J. Erby Wilkinson: Unit for Laboratory Animal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan 48109-2200, USA
Krystyna Frenkel: Environmental Medicine, NY University School of Medicine
Christy S. Carter: Wake Forest University School of Medicine, North Carolina 27157, USA
Marco Pahor: Wake Forest University School of Medicine, North Carolina 27157, USA
Martin A. Javors: The University of Texas Health Science Center at San Antonio, Texas 78229, USA
Elizabeth Fernandez: Geriatric Research, Education and Clinical Center and Research Service, South Texas Veterans Health Care System, and Barshop Institute for Longevity and Aging Studies, The University of Texas Health Science Center at San Antonio, Texas 78229, USA
Richard A. Miller: University of Michigan, and Ann Arbor VA Medical Center, Ann Arbor, Michigan 48109-2200, USA

Nature, 2009, vol. 460, issue 7253, 392-395

Abstract: Rapamycin for a longer life? The antitumour drug rapamycin targets TOR, a kinase that is part of the PI3K–AKT–mTOR cascade, involved in regulating protein translation, cell growth and autophagy. Reducing TOR function is known to extend the life of yeast, worms and flies. Now experiments replicated in three different laboratories demonstrate that rapamycin, fed to male and female mice in a dose that substantially inhibits TOR signalling, can extend their median and maximal lifespan by up to 14%. This life extension was observed in mice fed rapamycin from 270 days of age and also at a late stage in their life, from age 600 days. These findings point to the TOR pathway as a critical point in the control of ageing in mammals and in the pathogenesis of late-life illnesses.

Date: 2009
References: Add references at CitEc
Citations: View citations in EconPapers (11)

Downloads: (external link)
https://www.nature.com/articles/nature08221 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:460:y:2009:i:7253:d:10.1038_nature08221

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature08221

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().